Celularity
Clinical-stage biotechnology company productizing allogeneic cells and tissues derived from the postpartum placenta.
loading funding rounds…
Section 32(exited)
Celgene(exited)
Bill Maris(exited)
Sorrento Therapeutics(exited)
United Therapeutics(exited)
Human Longevity(exited)
Alumni Ventures(exited)
GX Acquisition Corp II(exited)
Starr Insurance(exited)
Dragasac(exited)
Palantir(exited)
Tony Robbins(exited)
| USD | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 49 % | (16 %) | 27 % | 138 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (458 %) | (454 %) | (785 %) | (326 %) | (74 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (1458 %) | (469 %) | 79 % | (862 %) | (107 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 369 % | 414 % | 436 % | 134 % | 32 % |
Source: Company filings or news article
Related Content
Analytics
Unlock the full power of analytics with a premium account
Track company size and historic growth
Track team composition and strength
Track website visits and app downloads
Tech stack
Tech stackLearn more about the technologies and tools that this company uses.
Investments by Celularity
Edit
ACQUISITION by Celularity Aug 2018